111 related articles for article (PubMed ID: 23503450)
21. Analysis of the pharmacodynamic activity of the mTOR inhibitor ridaforolimus (AP23573, MK-8669) in a phase 1 clinical trial.
Berk L; Mita MM; Kreisberg J; Bedrosian CL; Tolcher AW; Clackson T; Rivera VM
Cancer Chemother Pharmacol; 2012 May; 69(5):1369-77. PubMed ID: 22231376
[TBL] [Abstract][Full Text] [Related]
22. Rapamycin reverses NPM-ALK-induced glucocorticoid resistance in lymphoid tumor cells by inhibiting mTOR signaling pathway, enhancing G1 cell cycle arrest and apoptosis.
Gu L; Gao J; Li Q; Zhu YP; Jia CS; Fu RY; Chen Y; Liao QK; Ma Z
Leukemia; 2008 Nov; 22(11):2091-6. PubMed ID: 18685609
[TBL] [Abstract][Full Text] [Related]
23. Combined treatment with cisplatin and sirolimus to enhance cell death in human mesothelioma.
Hartman ML; Esposito JM; Yeap BY; Sugarbaker DJ
J Thorac Cardiovasc Surg; 2010 May; 139(5):1233-40. PubMed ID: 19853261
[TBL] [Abstract][Full Text] [Related]
24. Synergistic immunosuppressive effects of the mTOR inhibitor sirolimus and the phytochemical curcumin.
Deters M; Hütten H; Kaever V
Phytomedicine; 2013 Jan; 20(2):120-3. PubMed ID: 23079231
[TBL] [Abstract][Full Text] [Related]
25. Monitoring biological action of rapamycin in renal transplantation.
Leogrande D; Teutonico A; Ranieri E; Saldarelli M; Gesualdo L; Schena FP; Di Paolo S
Am J Kidney Dis; 2007 Aug; 50(2):314-25. PubMed ID: 17660033
[TBL] [Abstract][Full Text] [Related]
26. Arginine and Leucine regulate p70 S6 kinase and 4E-BP1 in intestinal epithelial cells.
Ban H; Shigemitsu K; Yamatsuji T; Haisa M; Nakajo T; Takaoka M; Nobuhisa T; Gunduz M; Tanaka N; Naomoto Y
Int J Mol Med; 2004 Apr; 13(4):537-43. PubMed ID: 15010853
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
[TBL] [Abstract][Full Text] [Related]
28. Biochemical monitoring of mTOR inhibitor-based immunosuppression following kidney transplantation: a novel approach for tailored immunosuppressive therapy.
Hartmann B; Schmid G; Graeb C; Bruns CJ; Fischereder M; Jauch KW; Heeschen C; Guba M
Kidney Int; 2005 Dec; 68(6):2593-8. PubMed ID: 16316335
[TBL] [Abstract][Full Text] [Related]
29. Arginine-induced stimulation of protein synthesis and survival in IPEC-J2 cells is mediated by mTOR but not nitric oxide.
Bauchart-Thevret C; Cui L; Wu G; Burrin DG
Am J Physiol Endocrinol Metab; 2010 Dec; 299(6):E899-909. PubMed ID: 20841502
[TBL] [Abstract][Full Text] [Related]
30. Cell size reduction induced by inhibition of the mTOR/S6K-signaling pathway protects Jurkat cells from apoptosis.
Fumarola C; La Monica S; Alfieri RR; Borra E; Guidotti GG
Cell Death Differ; 2005 Oct; 12(10):1344-57. PubMed ID: 15905878
[TBL] [Abstract][Full Text] [Related]
31. Ultraviolet-induced phosphorylation of p70(S6K) at Thr(389) and Thr(421)/Ser(424) involves hydrogen peroxide and mammalian target of rapamycin but not Akt and atypical protein kinase C.
Huang C; Li J; Ke Q; Leonard SS; Jiang BH; Zhong XS; Costa M; Castranova V; Shi X
Cancer Res; 2002 Oct; 62(20):5689-97. PubMed ID: 12384526
[TBL] [Abstract][Full Text] [Related]
32. Limitations in small intestinal neuroendocrine tumor therapy by mTor kinase inhibition reflect growth factor-mediated PI3K feedback loop activation via ERK1/2 and AKT.
Svejda B; Kidd M; Kazberouk A; Lawrence B; Pfragner R; Modlin IM
Cancer; 2011 Sep; 117(18):4141-54. PubMed ID: 21387274
[TBL] [Abstract][Full Text] [Related]
33. IL2-dependent phosphorylation of 40S ribosomal protein S6 is controlled by PI-3K/mTOR signalling in CTLL2 cells.
Tuhácková Z; Sloncová E; Vojtechová M; Sovová V
Int J Mol Med; 2004 Apr; 13(4):601-5. PubMed ID: 15010863
[TBL] [Abstract][Full Text] [Related]
34. Chemotherapy disrupts activity of translational regulatory proteins in bone marrow stromal cells.
Clutter SD; Fortney JE; Gibson LF
Exp Hematol; 2006 Nov; 34(11):1522-31. PubMed ID: 17046572
[TBL] [Abstract][Full Text] [Related]
35. The human glucagon-like peptide-1 analogue liraglutide regulates pancreatic beta-cell proliferation and apoptosis via an AMPK/mTOR/P70S6K signaling pathway.
Miao XY; Gu ZY; Liu P; Hu Y; Li L; Gong YP; Shu H; Liu Y; Li CL
Peptides; 2013 Jan; 39():71-9. PubMed ID: 23116613
[TBL] [Abstract][Full Text] [Related]
36. Novel pathway in Bcr-Abl signal transduction involves Akt-independent, PLC-gamma1-driven activation of mTOR/p70S6-kinase pathway.
Markova B; Albers C; Breitenbuecher F; Melo JV; Brümmendorf TH; Heidel F; Lipka D; Duyster J; Huber C; Fischer T
Oncogene; 2010 Feb; 29(5):739-51. PubMed ID: 19881535
[TBL] [Abstract][Full Text] [Related]
37. Requirement of androgen-dependent activation of protein kinase Czeta for androgen-dependent cell proliferation in LNCaP Cells and its roles in transition to androgen-independent cells.
Inoue T; Yoshida T; Shimizu Y; Kobayashi T; Yamasaki T; Toda Y; Segawa T; Kamoto T; Nakamura E; Ogawa O
Mol Endocrinol; 2006 Dec; 20(12):3053-69. PubMed ID: 16931574
[TBL] [Abstract][Full Text] [Related]
38. Adding protein to a carbohydrate supplement provided after endurance exercise enhances 4E-BP1 and RPS6 signaling in skeletal muscle.
Morrison PJ; Hara D; Ding Z; Ivy JL
J Appl Physiol (1985); 2008 Apr; 104(4):1029-36. PubMed ID: 18239077
[TBL] [Abstract][Full Text] [Related]
39. [Expression and clinical significance of serine-threonine kinase/mammalian target of rapamycin/p70 S6K signal path- way in oral squamous cell carcinoma].
Jieru J; Shuang L; Jiyuan L; Jun Z; Tang X
Hua Xi Kou Qiang Yi Xue Za Zhi; 2014 Oct; 32(5):504-8. PubMed ID: 25490832
[TBL] [Abstract][Full Text] [Related]
40. Potential natural mTOR inhibitors screened by in silico approach and suppress hepatic stellate cells activation.
Thiyagarajan V; Lee KW; Leong MK; Weng CF
J Biomol Struct Dyn; 2018 Dec; 36(16):4220-4234. PubMed ID: 29183268
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
